Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
FOCUS DIAGNOSTICS, INC.
RANDOX LABORATORIES

Accurate Epigenetic Test Eliminates Superfluous Biopsies for Prostate Cancer

By Labmedica International staff writers
Posted on 07 Aug 2014
Image: The photomicrograph shows the appearance of a low grade carcinoma of the prostate that can be difficult to recognize as malignancy, particularly in small needle biopsies (Photo courtesy of the University of Washington).
Image: The photomicrograph shows the appearance of a low grade carcinoma of the prostate that can be difficult to recognize as malignancy, particularly in small needle biopsies (Photo courtesy of the University of Washington).
Two independent trials have now validated the performance of an epigenetic test that could provide physicians with a better tool to help eliminate unnecessary repeat prostate biopsies.

Patients with a negative biopsy have been evaluated with an epigenetic test to identify those at low risk for harboring cancer missed through biopsy sampling error who could forego an unnecessary repeat biopsy.

Scientists at the James Buchanan Brady Urological Institute (Baltimore, MD, USA) working with colleagues from other institutes, evaluated the archived, cancer negative prostate biopsy core tissue samples of 350 subjects from a total of five urological centers in the USA. All subjects underwent repeat biopsy within 24 months with a negative (controls) or positive (cases) histopathological result. Centralized blinded pathology evaluation of the two biopsy series was performed in all available samples from each site.

Formalin fixed, paraffin embedded tissue cores were epigenetically profiled based on three genes: glutathione S-transferase pi (GSTP1), adenomatous polyposis coli (APC) and Ras association (RalGDS/AF-6) domain family 1 (RASSF1). GSTP1 methylation is a specific biomarker for prostate cancer and this gene is methylated in up to 90% of prostate cancer cases. Additionally, APC and RASSF1 are important field effect markers and increase the diagnostic sensitivity of the assay. Epigenetic analysis was performed in random, blinded fashion using a multiplex methylation specific polymerase chain reaction (MDxHealth; Irvine, CA, USA).

After correcting for age, prostate specific antigen (PSA), digital rectal exam, histopathological characteristics of the first biopsy, and race, this epigenetic test proved to be the most significant, independent, and strongest predictor of patient outcome with an odds ratio of 2.69 as well as the most valuable diagnostic aid of all evaluated risk factors. Alan W. Partin, MD, PhD, the lead author of the study said, “This epigenetic assay is a significant, independent predictor and has been shown to be the most valuable diagnostic aid of all evaluated risk factors in two independent trials. Negative findings of this assay could be used to reduce concern over unsampled cancer and effectively avoid unnecessary repeat biopsies.” The study was published online on April 18, 2014, in the Journal of Urology.

Related Links:

James Buchanan Brady Urological Institute
MDxHealth



ADVANCED INSTRUMENTS
PERIPHERAL VISIONS INC
DiagCor Bioscience
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel
Image: Histopathology of Breast Adenocarcinoma, × 20 magnification (Photo courtesy of Nikon).

Serum Protein Biomarkers Detect Invasive Breast Cancer

The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated. It has been estimated that... Read more

Industry News

view channel

Merck KGaA to Buy Sigma-Aldrich for USD 17 Billion

Merck KGaA (Darmstadt, Germany) will acquire Sigma-Aldrich (St. Louis, MO, USA) for USD 17 billion, expanding its business in North America and gaining exposure in Asia. All outstanding shares of Sigma-Aldrich will be acquired by Merck for USD 140 per share, which would represent a 37% premium to Sigma-Aldrich’s closing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.